Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Pharmacokinetics|Solid Tumor|Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Neoplasms
Interventions: DRUG: Boserolimab|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|DRUG: Carboplatin|DRUG: Nab-paclitaxel
Sponsor: Merck Sharp & Dohme LLC